Abeona Therapeutics (ABEO) Earnings Analysis
Abeona Therapeutics (ABEO) next reports earnings on 2026-08-13, consensus EPS -0.23 USD. Last quarter (2026-03-17) it beat with EPS -0.34 USD vs -0.35 USD est (+2.9%). It has beaten estimates in 5/6 recent quarters (83%). Trailing P/E 5.00.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does ABEO next report earnings?
| Next earnings date | 2026-08-13 |
|---|---|
| Consensus EPS estimate | -0.23 USD |
| Revenue estimate | 0.01B |
ABEO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-17 | -0.34 USD | -0.35 USD | +2.9% | Beat |
| 2025-08-14 | 1.71 USD | -0.39 USD | +538.5% | Beat |
| 2025-05-15 | -0.24 USD | -0.35 USD | +31.4% | Beat |
| 2025-03-20 | -0.24 USD | -0.43 USD | +44.2% | Beat |
| 2024-11-14 | -0.31 USD | -0.38 USD | +18.4% | Beat |
| 2024-08-12 | -0.75 USD | -0.33 USD | -127.3% | Miss |
Beat rate: 5/6 (83%) over reported quarters with consensus data.
ABEO valuation and analyst view
| Trailing P/E | 5.00 |
|---|---|
| Trailing EPS | 1.168 USD |
| Price / book | 2.51 |
| Dividend yield | 0.00% |
| Market cap | 0.37B |
| Analyst consensus | Buy (6 buy / 3 hold / 0 sell) |
| Avg price target | 17 USD |
Related research pages
Frequently asked questions
When is Abeona Therapeutics (ABEO)'s next earnings date?
Abeona Therapeutics is next scheduled to report on 2026-08-13, with a consensus EPS estimate of -0.23 USD and revenue estimate of 0.01B.
Did ABEO beat earnings last quarter?
In its 2026-03-17 report, ABEO posted EPS of -0.34 USD versus a -0.35 USD estimate — a beat of 2.9%.
What is ABEO's earnings track record?
Over the last 6 reported quarters with consensus data, ABEO beat estimates 5 times (83%).
What is ABEO's current P/E ratio and EPS?
ABEO trades at a trailing P/E of 5.00 on trailing EPS of 1.1680665026283572 USD.
What do analysts rate ABEO?
Analyst consensus is "Buy" across 9 ratings (0 strong buy, 6 buy, 3 hold, 0 sell, 0 strong sell). Average 12-month price target: 17 USD.